Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
Identifieur interne : 004526 ( Main/Exploration ); précédent : 004525; suivant : 004527Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
Auteurs : Baltazar Gomez-Mancilla [Canada] ; Paul J. Bédard [Canada]Source :
- Experimental Neurology [ 0014-4886 ] ; 1992.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Animal, Animals, Antiparkinson Agents (pharmacology), Antiparkinson agent, Chemotherapy, D2 Dopamine receptor, Dopamine Agents (pharmacology), Dopamine agonist, Experimental disease, Female, Indoles (pharmacology), MPTP Poisoning, Macaca fascicularis, Motor Activity (drug effects), Oxazines (pharmacology), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (physiopathology), Parkinson disease, Pathophysiology, Phenanthridines (pharmacology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Receptors, Dopamine D1, Receptors, Dopamine D2, Treatment.
- MESH :
- chemical , drug effects : Receptors, Dopamine.
- chemical , pharmacology : Antiparkinson Agents, Dopamine Agents, Indoles, Oxazines, Phenanthridines.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Motor Activity.
- chemical , physiology : Receptors, Dopamine.
- physiopathology : Parkinson Disease, Secondary.
- Animals, Female, MPTP Poisoning, Macaca fascicularis, Receptors, Dopamine D1, Receptors, Dopamine D2.
Abstract
A group of four drug naive Macaca fascicularis were rendered parkinsonian with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and then treated chronically with (+)-PHNO, a potent D2 agonist. After several days, dyskinesia appeared in all animals. At this point, the daily dose of (+)-PHNO was replaced by a dose of the D1 agonist CY 208–243. The substitution by CY 208–243 reproduced the same dyskinesia observed with (+)-PHNO. The administration of the DA synthesis inhibitor AMPT (α-methyl-p-tyrosine methyl ester) blocked the dyskinetic and antiparkinsonian effect of (+)-PHNO, and those effects were reestablished by the addition of a subthreshold dose of CY 208–243. Our results show that a selective D2 agonist is capable of inducing dyskinesia and suggest some kind of cooperation between D1 and D2 receptors in the antiparkinsonian and dyskinetic effect produced by (+)-PHNO.
Url:
DOI: 10.1016/0014-4886(92)90125-A
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001084
- to stream Istex, to step Curation: 001084
- to stream Istex, to step Checkpoint: 001D74
- to stream Main, to step Merge: 004D76
- to stream PascalFrancis, to step Corpus: 001082
- to stream PascalFrancis, to step Curation: 000E45
- to stream PascalFrancis, to step Checkpoint: 000F91
- to stream Main, to step Merge: 004F01
- to stream PubMed, to step Corpus: 001A54
- to stream PubMed, to step Curation: 001A54
- to stream PubMed, to step Checkpoint: 001A54
- to stream Ncbi, to step Merge: 000337
- to stream Ncbi, to step Curation: 000337
- to stream Ncbi, to step Checkpoint: 000337
- to stream Main, to step Merge: 004D10
- to stream Main, to step Curation: 004526
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys</title><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bédard">Paul J. Bédard</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B31C3D75B5E1CEEBF12CFD079976B43E21A12535</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0014-4886(92)90125-A</idno><idno type="url">https://api-v5.istex.fr/document/B31C3D75B5E1CEEBF12CFD079976B43E21A12535/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001084</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001084</idno><idno type="wicri:Area/Istex/Curation">001084</idno><idno type="wicri:Area/Istex/Checkpoint">001D74</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D74</idno><idno type="wicri:doubleKey">0014-4886:1992:Gomez Mancilla B:effect:of:chronic</idno><idno type="wicri:Area/Main/Merge">004D76</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:93-0029050</idno><idno type="wicri:Area/PascalFrancis/Corpus">001082</idno><idno type="wicri:Area/PascalFrancis/Curation">000E45</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F91</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000F91</idno><idno type="wicri:doubleKey">0014-4886:1992:Gomez Mancilla B:effect:of:chronic</idno><idno type="wicri:Area/Main/Merge">004F01</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:1354166</idno><idno type="wicri:Area/PubMed/Corpus">001A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A54</idno><idno type="wicri:Area/PubMed/Curation">001A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A54</idno><idno type="wicri:Area/PubMed/Checkpoint">001A54</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A54</idno><idno type="wicri:Area/Ncbi/Merge">000337</idno><idno type="wicri:Area/Ncbi/Curation">000337</idno><idno type="wicri:Area/Ncbi/Checkpoint">000337</idno><idno type="wicri:doubleKey">0014-4886:1992:Gomez Mancilla B:effect:of:chronic</idno><idno type="wicri:Area/Main/Merge">004D10</idno><idno type="wicri:Area/Main/Curation">004526</idno><idno type="wicri:Area/Main/Exploration">004526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys</title><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Centre de recherche en neurobiologie, Hôpital de l'Enfant-Jésus, 1401, 18e Rue, Quebec City</wicri:regionArea><wicri:noRegion>Quebec City</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University, Quebec City</wicri:regionArea><wicri:noRegion>Quebec City</wicri:noRegion></affiliation></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bédard">Paul J. Bédard</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Centre de recherche en neurobiologie, Hôpital de l'Enfant-Jésus, 1401, 18e Rue, Quebec City</wicri:regionArea><wicri:noRegion>Quebec City</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University, Quebec City</wicri:regionArea><wicri:noRegion>Quebec City</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Experimental Neurology</title><title level="j" type="abbrev">YEXNR</title><idno type="ISSN">0014-4886</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">117</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="185">185</biblScope><biblScope unit="page" to="188">188</biblScope></imprint><idno type="ISSN">0014-4886</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-4886</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Animals</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>D2 Dopamine receptor</term><term>Dopamine Agents (pharmacology)</term><term>Dopamine agonist</term><term>Experimental disease</term><term>Female</term><term>Indoles (pharmacology)</term><term>MPTP Poisoning</term><term>Macaca fascicularis</term><term>Motor Activity (drug effects)</term><term>Oxazines (pharmacology)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Parkinson disease</term><term>Pathophysiology</term><term>Phenanthridines (pharmacology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Indoles</term><term>Oxazines</term><term>Phenanthridines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>MPTP Poisoning</term><term>Macaca fascicularis</term><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>MPTP</term><term>Parkinson maladie</term><term>Pathologie expérimentale</term><term>Physiopathologie</term><term>Récepteur dopaminergique D2</term><term>Stimulant dopaminergique</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A group of four drug naive Macaca fascicularis were rendered parkinsonian with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and then treated chronically with (+)-PHNO, a potent D2 agonist. After several days, dyskinesia appeared in all animals. At this point, the daily dose of (+)-PHNO was replaced by a dose of the D1 agonist CY 208–243. The substitution by CY 208–243 reproduced the same dyskinesia observed with (+)-PHNO. The administration of the DA synthesis inhibitor AMPT (α-methyl-p-tyrosine methyl ester) blocked the dyskinetic and antiparkinsonian effect of (+)-PHNO, and those effects were reestablished by the addition of a subthreshold dose of CY 208–243. Our results show that a selective D2 agonist is capable of inducing dyskinesia and suggest some kind of cooperation between D1 and D2 receptors in the antiparkinsonian and dyskinetic effect produced by (+)-PHNO.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></noRegion><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bédard">Paul J. Bédard</name><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bédard">Paul J. Bédard</name><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004526 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004526 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B31C3D75B5E1CEEBF12CFD079976B43E21A12535
|texte= Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
}}
| This area was generated with Dilib version V0.6.29. |  |